Accession Number:

ADB101198

Title:

Chemotherapy of Leishmaniasis.

Descriptive Note:

Annual progress rept. no. 9, 1 Jan 83-15 Jan 84,

Corporate Author:

GEORGIA UNIV ATHENS

Report Date:

1984-01-01

Pagination or Media Count:

84.0

Abstract:

Three day infections of Leishmania donovani in the golden hamster primary visceral test system were used to test a total of 581 compounds 564 new compounds and 17 requiring additional testing or antileishmanial activity against visceral leishmaniasis and 19 day infections of L. braziliensis panamensis in the golden hamster primary cutaneous test system were used to test a total of 21 compounds for activity against cutaneous infections. One hundred and fifty-six of the 581 compounds tested in the primary visceral test system were observed to have significant suppressive activity against L. donovani at one or more drug dosage levels. A total of 41 of these active compounds had significant suppressive activity to warrant the calculation of the Glucantime Index. Twenty-four of these had suppressive activity greater than the reference compound, Glucantime, 10 had activity equivalent to that of Glucantime, while seven had activity less than Glucantime. Nine of the 21 compounds tested in the primary cutaneous test system were noted to have significant suppressive activity against L. braziliensis panamensis at one or more drug dosage levels. Two of these active compounds had sufficient antilesishmanial activity to warrant the calculation fo a Glucantime Index. The activity of these two compounds was similar to that of Glucantime. Extensive studies were carried out with formycin B, WR 6026, WR238605, and Glucantime to investigate further the optimum treatment regimen. Keywords Antimony resistance Primaquine resistance Owl monkeys Optimization studies Curative studies Data processing and Dogs.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE